NMNH Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 90 days continuous (based on the active human trial); no established off-cycle break duration
• Frequency: Once daily, morning preferred
• Common delivery routes: Oral capsule (the only form with any human use; injectable NMNH has no validated safety data)
• Key timing notes: Morning dosing aligns with natural energy rhythms; evening dosing risks sleep disruption due to NMNH's sustained NAD+ elevation effect

Who This Protocol Is For

NMNH draws interest from people who have already explored NMN or other NAD+ precursors and want something that may produce a stronger or more sustained effect. Because NMNH is an investigational compound with a single active human clinical trial and no published human results as of this writing, the people who tend to look into it are generally not beginners to the NAD+ space. They have some familiarity with how NAD+ precursors work and are following the clinical trial data closely.

The goals most commonly associated with NMNH are the same ones that drive interest in NMN: supporting energy metabolism, maintaining cognitive clarity, protecting mitochondrial function as people age, and general longevity-focused health maintenance. Because NMNH elevates NAD+ at a meaningfully higher level than NMN in animal studies and sustains that elevation for longer, some users view it as the higher-potency option worth investigating once they have a baseline understanding of the compound class.

Experience level matters here more than with well-established supplements. People considering NMNH typically understand the difference between established safety data and emerging research, and are comfortable operating with less certainty than a compound with years of human trial data would provide. If you are new to NAD+ precursors, NMN has a substantially larger body of human data and may be the more appropriate starting point.

Preferred delivery method for NMNH is oral capsule, the only form used in human research. There is no validated injectable NMNH protocol, and attempting to inject NMNH is not supported by any published safety data.

How Is an NMNH Cycle Structured?

NMNH runs as a flat daily dose for 90 days with no distinct phases and no mandated break at the end. It does not follow the loading-then-maintenance-then-off-cycle arc that characterizes many injectable peptide protocols, because NMNH is not a peptide. It is a small-molecule NAD+ precursor. The goal is to maintain elevated NAD+ levels consistently throughout the cycle window rather than to front-load or taper. Human data for NMNH is still emerging from a single active clinical trial, so this 90-day continuous framework is the closest thing to an established protocol.

Think of it less like a peptide cycle with phases and more like a sustained supplementation period: one daily dose, taken at the same time each morning, across the length of the cycle.

Practitioners familiar with the broader NAD+ precursor space sometimes apply cycling frameworks borrowed from NMN, which often follow a five-days-on, two-days-off weekly rhythm or a three-weeks-on, one-week-off pattern. Whether those patterns translate meaningfully to NMNH is an open question, and no published evidence establishes them as a requirement for this compound. The timing considerations and off-cycle question are each addressed in their own sections below.

How Your Dose Is Determined

What moves an NMNH dose:

• Your goal: NMNH is most commonly considered for energy metabolism support, mitochondrial health, cognitive maintenance, and longevity-focused NAD+ optimization. General wellness and metabolic support goals tend toward the conservative end of what has been tested in humans. More aggressive optimization goals do not yet have a validated higher-dose protocol to draw on.
• Experience level: Someone new to NAD+ precursors will generally start at the lower end of what has been used in human research. Someone with prior NMN experience who is making a considered switch to NMNH may approach the dose differently, though structural similarity to NMN does not mean the doses are interchangeable.
• Delivery route: The only route with any human data is oral capsule. The dose used in the active human trial is the most conservative and evidence-grounded reference available. Higher oral doses extrapolated from NMN human trials exist as a reference point but are not NMNH-validated.
• Individual response: NMNH's mechanism includes suppression of glycolysis and induction of reductive stress, a form of cellular metabolic adjustment. How a given person's system responds to that mechanism is not yet well characterized in humans, which is why starting conservatively and observing the response before any adjustments reflects what the evidence supports.

There is no single NMNH dose that fits everyone. The only dose tested in a formal human trial sits at the modest end of the theoretical range, while animal-study doses translate to figures that are not appropriate for self-directed human use. The gap between those two anchors is meaningful. Navigating it responsibly requires accounting for your health profile, any relevant contraindications, and whether you are using it alongside other compounds.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your goal (energy metabolism, mitochondrial health, or longevity support), your prior experience with NAD+ precursors, and whether you are new to NMNH or transitioning from a related compound and builds your NMNH protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take NMNH?

NMNH is taken once daily. That single-dose daily rhythm is what the active human trial uses, and it fits the compound's pharmacological profile. NMNH has an approximate half-life of 2.4 days and produces a sustained NAD+ elevation lasting at least 24 hours, so a single morning dose maintains consistent NAD+ support without stacking on top of an active prior dose. The trial administers the daily amount as two capsules taken together, which is a formulation detail rather than a split-dose scheduling strategy.

Morning dosing is the consistent recommendation across the NAD+ precursor literature, and it applies to NMNH with particular force. NMNH triggers sustained energy-pathway activation, so taking it in the evening risks disrupting sleep. Taking it with breakfast aligns with natural energy production rhythms and reduces the likelihood of nausea that can occur on an empty stomach.

Consistency across days matters more than the precise clock time. Taking NMNH at roughly the same time each morning allows NAD+ levels to stabilize rather than fluctuate, which is the underlying goal of a sustained precursor protocol.

Loading and Maintenance Phases

NMNH does not use a loading and maintenance phase structure. The only established human protocol is a flat daily dose maintained consistently across the full 90-day cycle, without a front-loaded higher dose at the start or a stepped-down maintenance dose afterward.

This is a meaningful difference from injectable NAD+ protocols, which often begin with a higher-frequency loading period designed to saturate cellular reserves quickly before dropping to a lower-frequency maintenance schedule. That structure reflects the pharmacokinetics of intravenous or subcutaneous NAD+ delivery. Oral NMNH, with its longer half-life and sustained elevation profile, does not require the same rapid front-loading approach. The once-daily dose at a consistent level is the protocol shape the evidence supports.

If you have seen NAD+ loading protocols referenced alongside NMNH, they almost certainly describe injectable NAD+ therapy, not oral NMNH. The two share a biological endpoint, raising NAD+, but the delivery mechanism, pharmacokinetics, and dosing structure are distinct. Applying an injectable NAD+ loading framework to oral NMNH does not follow from the available evidence.

Off-Cycle Considerations

The active human trial runs 90 consecutive days with no mandated off-cycle break. That is the only formal protocol structure in the published research, and no published guidance establishes a required rest period after a completed NMNH cycle.

Practitioners working with NAD+ precursors more broadly sometimes apply a sensitivity-reset break after extended continuous use, typically one to two weeks, when users report that the subjective effects seem to diminish after months of consistent dosing. Whether that pattern applies to NMNH is not established, but the reasoning is borrowed from general NAD+ precursor experience.

The more conservative position is to treat the 90-day continuous framework as the reference point and consult a healthcare provider about what follows. Because NMNH's long-term safety in humans has not been established, indefinite continuous use without reassessment is not supported by current evidence. Complete the cycle, evaluate the response, and make a decision about continuation under medical guidance.

What to Expect Week by Week

NMNH has no published human results timeline. What follows draws on NMN human trial data, the closest validated reference point, alongside the broader NAD+ precursor literature. NMNH is expected to be more potent than NMN based on animal data, but whether that translates to a faster or more pronounced human timeline remains to be confirmed.

• Week 1 to 2: Early effects, if any, tend to be subtle. People who are significantly NAD+ deficient may notice a shift in energy levels or mental clarity within the first week. For most, the first two weeks reflect cellular systems adjusting to elevated NAD+ availability, with little that is overtly noticeable.
• Week 3 to 4: More stable energy across the day and improved sleep quality are among the most commonly reported changes in NMN human trial data at this stage. Cognitive steadiness, particularly the absence of afternoon energy dips, is a frequent early observation.
• Week 5 to 8: This is the window where meaningful change tends to become more apparent across the NAD+ precursor literature. Endurance and physical performance markers begin to shift in NMN studies, and NAD+ blood levels show measurable elevation. In one NMN human trial, NAD+ levels rose roughly 40 percent at the 8-week mark.
• Beyond 8 weeks: NMN human trials at the 12-week mark show continued improvement in physical performance measures including walking speed and muscle function. The 90-day NMNH trial is designed to capture tolerability and safety across this longer window.

When a well-structured NMNH cycle goes as it should, the arc that emerges from comparable NAD+ precursor experience is a gradual, accumulating shift in metabolic energy and cognitive stability, not a dramatic day-one change. Users who maintain consistent morning dosing across the full cycle commonly report that the most noticeable effects, cleaner energy, reduced fatigue, and steadier focus, consolidate in the back half of the cycle. These timelines are observed patterns from the broader NAD+ precursor literature, not guarantees specific to NMNH. Individual results vary based on baseline NAD+ status, consistency, and individual response.

Common Protocol Mistakes

Applying animal-study doses to a human protocol. Animal studies characterizing NMNH's NAD+-elevating potency used doses that translate to very large amounts per kilogram of body weight. Those figures are not human starting points. They are research doses designed to detect effects in a controlled model, and high-dose NAD+ precursors carry real hepatotoxicity risk in humans at extreme intake levels. The dose used in the active human trial is the evidence-grounded human reference. More is not better here, particularly with a compound whose human dose-response curve has not yet been mapped.

Confusing NMNH with NMN, NAD+, or an injectable compound. This mistake has real consequences. NMNH is not NMN, is not injectable NAD+, and is not a peptide. Each compound has a different dosing structure, different safety profile, and different administration route. Applying an injectable NAD+ protocol to oral NMNH, or assuming NMN doses translate directly to NMNH, leads to the wrong framework. Always confirm which compound and which form you are working with before selecting a protocol.

Dosing in the evening. NMNH produces a sustained NAD+ elevation lasting at least 24 hours. That elevated metabolic activity is compatible with a productive day and incompatible with falling asleep easily. Evening dosing is a consistent source of sleep disruption for NAD+ precursor users, and NMNH's longer elevation duration makes this a more significant concern than with NMN. Morning dosing with breakfast is the standard approach, and there is a clear pharmacological reason for it.

Double-dosing after a missed session. Skipping a day does not mean taking twice the amount the next morning. Doubling spikes NAD+ levels sharply rather than maintaining steady elevation and increases the likelihood of acute side effects including nausea, flushing, and diarrhea. The correct response to a missed dose is to resume the regular schedule at the next scheduled time.

Ignoring signs that something is wrong. NMNH's most common side effects are gastrointestinal: nausea, headache, stomach upset, and diarrhea. These often resolve as the body adjusts, particularly when the capsule is taken with food. Side effects that persist beyond two to three days, or any sign of liver stress such as yellowing of the skin or eyes, dark urine, or severe fatigue, are not something to push through. Stop use and consult a healthcare provider promptly.

Sourcing without verification. NMNH is an investigational compound, and the market for NAD+ precursors includes products with widely variable quality. Using a product without independent quality verification introduces real uncertainty about what you are actually taking. Manufacturing standards and third-party testing matter more for a compound where the human safety picture is still being established, not less.

NMNH is not FDA-approved for any therapeutic use and is currently under study as an investigational compound. Athletes competing in tested sports should confirm the regulatory standing of any NAD+ precursor with their relevant sporting body before use.

Frequently Asked Questions

How long is a typical NMNH cycle?

The only established human protocol runs 90 consecutive days, drawn from the active clinical trial studying NMNH. No shorter or longer standard has been published in the literature. Your personalized cycle length, including any break that follows, is built based on your specific situation in the MyPeptidePal Protocol Creator.

How often do you take NMNH?

NMNH is taken once daily, with morning timing strongly preferred. The compound produces a sustained NAD+ elevation lasting at least 24 hours, so a single daily dose maintains consistent levels without stacking. Evening dosing risks sleep disruption and is consistently avoided across the NAD+ precursor literature.

Does NMNH need a loading phase?

No. NMNH is run at a flat daily dose throughout the cycle with no established loading phase. This differs from injectable NAD+ protocols, which often front-load to saturate cellular reserves quickly. Oral NMNH's longer half-life and sustained elevation profile make that rapid front-loading approach unnecessary.

Do you need to cycle off NMNH?

The active human trial runs 90 continuous days with no mandated off-cycle break, so no required rest period is established in the current evidence. Because NMNH's long-term human safety data has not been established, completing a cycle and reassessing under medical guidance before continuing is the conservative and evidence-consistent approach.

Is NMNH actually a peptide?

No. NMNH is a small-molecule NAD+ precursor, specifically the reduced form of NMN. Peptides are chains of amino acids; NMNH is a nucleotide-based molecule. The label "NMNH peptide" appears in some online forums and marketing materials, but it is a misclassification. Using the wrong label can lead to applying the wrong protocol framework, which matters for both safety and outcomes.

How does NMNH compare to NMN for protocol purposes?

NMN has a substantially larger body of human trial data, a well-established safety profile, and more real-world protocol experience. NMNH is expected to elevate NAD+ more potently and for a longer duration based on animal studies, but that theoretical advantage comes alongside much thinner human evidence. For people new to NAD+ precursors or prioritizing a compound with confirmed human safety data, NMN is the more evidence-grounded choice at this stage.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world protocols for NMNH in one place.